Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 10, 2015Please join us for a Boston Scientific press event. Protection from sudden cardiac death, just under the skin: the EMBLEM™ Subcutaneous ICD System
SAVE THE DATE: June 23, 2015. Milan, Italy. Enterprise Hotel Corso Sempione, 91-93 20149 Milan, Italy We would like to invite you to our press event on June 23, 2015 dedicated to an innovative,...
-
Jun 10, 2015Einladung zur Presseveranstaltung von Boston Scientific. Schutz vor plötzlichem Herzstillstand, direkt unter der Haut: das EMBLEM™ Subkutane-ICD System.
SAVE THE DATE: 23. Juni 2015. Mailand, Italien. Enterprise Hotel Corso Sempiore, 91-03 20149 Mailand, Italien Wir möchten Sie herzlich zu unserer Presseveranstaltung am 23. Juni 2015 rund um das...
-
Jun 10, 2015
¡RESERVA LA FECHA!: JUNIO 23, 2015. Milán, Italia. Enterprise Hotel Corso Sempione, 91-93 20149 Milán, Italia Es un placer invitarte al evento de prensa que tendrá lugar el próximo 23 de...
-
Jun 5, 2015El dispositivo de 16 contactos y batería desechable de alta capacidad más pequeña del mundo expande la oferta del sistema de estimulación de la médula espinal
Boston Scientific anuncia la comercialización del sistema Precision Novi™ para la estimulación de la médula espinal (EME) en la Sociedad Internacional de Neuromodulación en Montreal,...
-
Jun 4, 2015
World’s Smallest 16-Contact High-Capacity Primary Cell Device Expands Spinal Cord Stimulator System Offering Boston Scientific announces the European launch of the Precision Novi™ Spinal Cord...
-
Jun 4, 2015Das weltweit kleinste 16-Kontakt-Gerät mit Hochleistungs-Primärzelle erweitert das Angebot im Bereich der Rückenmarkstimulation
Im Rahmen des Kongresses der International Neuromodulation Society in Montreal, Kanada, kündigte Boston Scientific die europäische Markteinführung des Precision Novi™-Systems zur...
-
May 20, 2015
Compelling Results Presented at EuroPCR 2015 Add to Growing Body of Evidence Supporting Performance and Safety A new study evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System...
-
May 19, 2015Additional Data from EVOLVE II Pivotal Trial Demonstrate Safety and Performance in Patients with Diabetes at One Year.
Boston Scientific (NYSE: BSX) reported positive, long-term data from the EVOLVE Trial of the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System, with no...
-
Apr 28, 2015MAJESTIC Trial Meets Performance Endpoint With Compelling Results
In an important clinical advancement in the treatment of peripheral artery disease (PAD), a key trial evaluating the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System met...
-
Apr 27, 2015
Boston Scientific Corporation (NYSE: BSX) announces a collaboration with Brainlab AG, a leading software-driven medical technology company that helps improve patient treatment planning and...
-
Apr 8, 2015
Boston Scientific Corporation (NYSE: BSX) hat die angekündigte Vereinbarung mit Endo International plc (NASDAQ: ENDP) (TSX: ENL) zur Übernahme der Bereiche Men’s Health und Prostate Health von...
-
Mar 19, 2015Innovative device offers first-line treatment for patients at risk of sudden cardiac arrest
Boston Scientific Corporation (NYSE: BSX) has received FDA and CE Mark approval of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System. The EMBLEM S-ICD System is a treatment...
-
Mar 13, 2015First-Of-Its-Kind Alternative to Long-Term Warfarin Therapy for Stroke Risk Reduction in Patients with Non-Valvular Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN Left Atrial Appendage Closure Device. The WATCHMAN Device offers a new...
-
Mar 13, 2015Un dispositivo innovador que ofrece una alternativa al tratamiento con warfarina a largo plazo para reducir el riesgo de ictus en los pacientes con fibrilación auricular no valvular.
Boston Scientific Corporation (NYSE: BSX) ha recibido la aprobación de su dispositivo WATCHMAN para el cierre de la orejuela auricular izquierda por parte de la Administración de alimentos y...
-
Oct 16, 2014The innovative devices allow pacemaker patients access to full body MRI scans in 1.5 Tesla and 3.0 Tesla systems
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the ACCOLADETM pacemaker family. When implanted with the company's INGEVITYTM leads, ACCOLADE pacemakers are the first...
-
Oct 16, 2014The innovative devices allow pacemaker patients access to full body MRI scans in 1.5 Tesla and 3.0 Tesla systems
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the ACCOLADETM pacemaker family. When implanted with the company's INGEVITYTM leads, ACCOLADE pacemakers are the first...
-
Oct 9, 2014Comprehensive Clinical Data from Randomized Trials Reviewed
After reviewing updated data and analysis for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, the U.S. Food and Drug Administration (FDA)...
-
Oct 7, 2014La nuova tecnologia consente di affrontare patologie cardiache complesse che colpiscono in Europa 1,2 milioni di pazienti
I primi impianti, effettuati in questo periodo con la collaborazione di medici specialisti europei, hanno avuto risultati positivi e hanno consentito all’équipe medica di acquisire competenze...
-
Oct 2, 2014
Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently,...
-
Oct 2, 2014
Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently,...
-
Sep 29, 2014
New data for the Lotus™ Valve System announced at PCR London Valves 30-Day outcomes for the 250 patients enrolled in REPRISE II Extended Cohort trial were presented by Prof Ian Meredith at PCR...
-
Sep 29, 2014Neue Daten für das Lotus™-Klappensystem beim PCR London Valves Kongress vorgestellt
Prof. Ian Meredith hat im Rahmen des PCR London Valves Kongresses am Montag 30-Tage-Daten der REPRISE-II-Extension vorgestellt, die 250 Patienten einschließt. REPRISE II, eine Studie zur...
-
Sep 25, 2014Nuovi dati per la valvola Lotus™ presentati al congresso PCR London Valves
I dati a 30 giorni per i 250 pazienti arruolati nello studio di coorte esteso REPRISE II sono stati presentati il 29 settembre dal Professor Ian Meredith nell'ambito del congresso PCR London...
-
Sep 23, 2014Data From REPRISE III Clinical Trial Designed to Support U.S. Regulatory Approval
Boston Scientific Corporation (NYSE: BSX) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus™ Valve System in patients with...
-
Sep 18, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...